Namenda
(Memantine)ApprovedSmall molecule
AbbVieMemantine is used to treat moderate to severe Alzheimer's disease by helping to slow down memory loss and confusion. It works by regulating glutamate, a chemical in the brain involved in learning and memory.[2] Namenda is currently approved and in use across 68 indications[4].[1]
Namenda is one of 1202 small molecule programs targeting Neurodegenerative Disease. It is currently in Approved.
68
Indications
165
Total Trials
17
Active Trials
1,201
Competitors
3
FDA Applications
NDA/BLA/ANDA regulatory filings
2
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 66 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Namenda
AbbVieApproved
Halaven
EisaiPreclinical
Trodelvy
GileadPreclinical
Adriamycin
GGynecologic Oncology Group
Preclinical
DATROWAY
Daiichi SankyoPreclinical
MS Contin
Merck & Co.Preclinical
Blenoxane
Bristol-Myers SquibbPreclinical
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Avastin
RochePreclinical
Paracetamol
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Alzheimer's Disease14 trials
Show 11 more trials
The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease
Completed·—·Phase 4·NCT01921972·232 enrolled
Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease
Completed·—·Phase 4·NCT00476008·60 enrolled
Schizophrenia8 trials
Show 5 more trials
Memantine for the Treatment of Cognitive Dysfunction and Negative Symptoms in Patients With Chronic Schizophrenia
Terminated·—·Phase 3·NCT00148616·13 enrolled
Memantine for the Prevention of Cognitive Dysfunction and Negative Symptoms in Patients With Acute Schizophrenia
Terminated·—·Phase 3·NCT00148590·24 enrolled
Cognitive impairment5 trials
Effect of Memantine on Radiotherapy-related Cognitive Impairment
Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2/3·NCT03342443·240 enrolled
Moderate to Severe Alzheimer's Disease5 trials
Show 2 more trials
Bipolar Disorder4 trials
Show 1 more trial
87 more indications
Memory4 trials
Dementia4 trials
Show 1 more trial
Treatment4 trials
Cross-over Comparison of Gabapentin and Memantine as Treatment for Acquired Nystagmus
Completed·—·N/A·NCT00928954·10 enrolled
Show 1 more trial
Amyotrophic Lateral Sclerosis4 trials
Agitation3 trials
Memantine for Agitation in Dementia
Completed·—·Phase 4·NCT00371059·153 enrolled
Autism Spectrum Disorder3 trials
Obsessive-Compulsive Disorder3 trials
Autism3 trials
Cognition3 trials
Parkinson's Disease3 trials
Brain Injury3 trials
Neuropathic Pain3 trials
Whole-Brain Radiotherapy3 trials
Brain Metastases2 trials
Glaucoma2 trials
Systemic Lupus Erythematosus2 trials
Single Dose2 trials
Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge
Active, not recruiting·—·Phase 2·NCT05418049·45 enrolled
Post Operative Pain2 trials
Memantine and Postoperative Pain
Terminated·—·Phase 4·NCT01032759·77 enrolled
Aphasia2 trials
Frontotemporal Dementia2 trials
Multiple Sclerosis2 trials
Memantine Therapy for Multiple Sclerosis
Terminated·—·Phase 2·NCT00638833·20 enrolled
Down syndrome2 trials
MPA2 trials
Fed1 trial
Metabolism1 trial
Effect of Acetylcholinesterase Inhibitors on Bone Metabolism
Recruiting·—·Phase 2·NCT06041789·45 enrolled
Alcohol Dependence1 trial
A Placebo-Controlled Trial of Memantine for Alcohol Dependence
Completed·NNational Institute on Alcohol Abuse and Alcoholism (NIAAA)·Phase 2·NCT00246415·90 enrolled
Adult1 trial
Brain Metastases From Solid Tumors1 trial
AIN1 trial
Post-Traumatic Stress Disorder1 trial
Women1 trial
Transcranial Magnetic Stimulation1 trial
Migraine1 trial
Cognitive Functions1 trial
Peripheral Neuropathy1 trial
Bipolar Depression1 trial
Acute1 trial
Huntington's Disease1 trial
Study of Memantine to Treat Huntington's Disease
Completed·—·Phase 4·NCT00652457·50 enrolled
Alzheimer disease1 trial
Relapse1 trial
Radiation Therapy1 trial
Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain
Not yet recruiting·TThe University of Texas Health Science Center at San Antonio·Phase 2·NCT07470606·108 enrolled
Partial Epilepsy1 trial
Cognitive Function1 trial
Early Application of Memantine and Pioglitazone to Protect Cognitive Function After Radiotherapy
Not yet recruiting·—·Phase 2·NCT06594172·67 enrolled
Neurodegenerative Disease1 trial
Monotherapy1 trial
Bulimia Nervosa1 trial
Atrophy1 trial
Fibromyalgia1 trial
Randomised Controlled Trial of Memantine in Fibromyalgia
Unknown status·—·Phase 3·NCT01653457·60 enrolled
Cognitive Deficit1 trial
AIDS dementia1 trial
A Study to Evaluate the Use of Memantine In Combination With Anti-HIV Drugs to Treat AIDS Dementia Complex (ADC)
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000867·120 enrolled
Rehabilitation1 trial
Neurotoxicity1 trial
Psychosis1 trial
Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis
Recruiting·—·Phase 1·NCT04789915·46 enrolled
Skin-Picking1 trial
Major Depressive Disorder (MDD)1 trial
Glioma of Brain1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
Oct 16, 2003
NAMENDA
NDA NDA021487
Apr 18, 2005
NAMENDA
NDA NDA021627
Jun 21, 2010
NAMENDA XR
NDA NDA022525
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Namenda drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Memantine. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Patent Landscape[6]
Patent Cliff
Mar 24, 2029
Earliest patent expiration — generic entry possible after this date